Cargando…

Correlation between treatment plan parameters and particular prognostic factors in prostate cancer treated with high–dose–rate brachytherapy (HDR–BT) as a boost

PURPOSE: Certain constraints for target coverage and dose limits in Organs at Risk (OARs) shows some evidence that doses values and homogeneity index in treated volume depends on prognostic factors such as prostate volume, location of urethra and the number of inserted applicators. Our study is to d...

Descripción completa

Detalles Bibliográficos
Autores principales: Chicheł, Adam, Kanikowski, Marek, Skowronek, Janusz, Dymnicka, Magdalena, Piotrowski, Tomasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080389/
https://www.ncbi.nlm.nih.gov/pubmed/27799948
_version_ 1782462702223884288
author Chicheł, Adam
Kanikowski, Marek
Skowronek, Janusz
Dymnicka, Magdalena
Piotrowski, Tomasz
author_facet Chicheł, Adam
Kanikowski, Marek
Skowronek, Janusz
Dymnicka, Magdalena
Piotrowski, Tomasz
author_sort Chicheł, Adam
collection PubMed
description PURPOSE: Certain constraints for target coverage and dose limits in Organs at Risk (OARs) shows some evidence that doses values and homogeneity index in treated volume depends on prognostic factors such as prostate volume, location of urethra and the number of inserted applicators. Our study is to determine the relation between values of the doses in prostate, OARs and particular prognostic factors related to HDR-BT of prostate cancer. MATERIAL AND METHODS: The amount of 190 patients with localized prostate cancer were treated with interstitial HDR-BT between July 2006 and July 2007. The HDR-BT was administered as a boost for previously delivered 50 Gy dose from external beam radiotherapy. Dose volume parameters were determined such as: D(min), D(max), D(mean), D(90), V(100), V(150) and V(200) for prostate and D(min), D(max), D(mean), D(10) and V(100) for urethra and rectum (OARs), respectively. These parameters were correlated with prognostic factors such as: age, staging (TNM), Gleason score, initial PSA level (i-PSA), number of needles and volume of the prostate. RESULTS: The mean value of D(90) was 91.3%, range 65.9-102.8%. Mean urethral D(10) was 121, 8%, range 78.8-152.9%. Mean rectal D(10) was 81.3%, range 37.4-101.0%. Statistically significant relationship was found between staging (TNM), prostate volume, and the number of needles used for implant and increased prostate D(90) and decreased V(200). The prognostic factor was only the age which was related to increased urethral D(10) and D(max). No correlation was found between any prognostic factor and rectal wall DVH parameters. CONCLUSIONS: Increased prostate volume with improved D(90) and greater number of implanted needles results in better target coverage (higher V(100)), better dose distribution (lower V(200)) and decreased dose delivered to the urethra (lower urethral D(10), D(max)), with no evident influence on rectal wall. Further investigation with closed follow-up should give an answer whether the above corresponds with morbidity and outcome.
format Online
Article
Text
id pubmed-5080389
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-50803892016-10-31 Correlation between treatment plan parameters and particular prognostic factors in prostate cancer treated with high–dose–rate brachytherapy (HDR–BT) as a boost Chicheł, Adam Kanikowski, Marek Skowronek, Janusz Dymnicka, Magdalena Piotrowski, Tomasz J Contemp Brachytherapy Original Article PURPOSE: Certain constraints for target coverage and dose limits in Organs at Risk (OARs) shows some evidence that doses values and homogeneity index in treated volume depends on prognostic factors such as prostate volume, location of urethra and the number of inserted applicators. Our study is to determine the relation between values of the doses in prostate, OARs and particular prognostic factors related to HDR-BT of prostate cancer. MATERIAL AND METHODS: The amount of 190 patients with localized prostate cancer were treated with interstitial HDR-BT between July 2006 and July 2007. The HDR-BT was administered as a boost for previously delivered 50 Gy dose from external beam radiotherapy. Dose volume parameters were determined such as: D(min), D(max), D(mean), D(90), V(100), V(150) and V(200) for prostate and D(min), D(max), D(mean), D(10) and V(100) for urethra and rectum (OARs), respectively. These parameters were correlated with prognostic factors such as: age, staging (TNM), Gleason score, initial PSA level (i-PSA), number of needles and volume of the prostate. RESULTS: The mean value of D(90) was 91.3%, range 65.9-102.8%. Mean urethral D(10) was 121, 8%, range 78.8-152.9%. Mean rectal D(10) was 81.3%, range 37.4-101.0%. Statistically significant relationship was found between staging (TNM), prostate volume, and the number of needles used for implant and increased prostate D(90) and decreased V(200). The prognostic factor was only the age which was related to increased urethral D(10) and D(max). No correlation was found between any prognostic factor and rectal wall DVH parameters. CONCLUSIONS: Increased prostate volume with improved D(90) and greater number of implanted needles results in better target coverage (higher V(100)), better dose distribution (lower V(200)) and decreased dose delivered to the urethra (lower urethral D(10), D(max)), with no evident influence on rectal wall. Further investigation with closed follow-up should give an answer whether the above corresponds with morbidity and outcome. Termedia Publishing House 2009-03-23 2009-03 /pmc/articles/PMC5080389/ /pubmed/27799948 Text en Copyright: © 2009 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Original Article
Chicheł, Adam
Kanikowski, Marek
Skowronek, Janusz
Dymnicka, Magdalena
Piotrowski, Tomasz
Correlation between treatment plan parameters and particular prognostic factors in prostate cancer treated with high–dose–rate brachytherapy (HDR–BT) as a boost
title Correlation between treatment plan parameters and particular prognostic factors in prostate cancer treated with high–dose–rate brachytherapy (HDR–BT) as a boost
title_full Correlation between treatment plan parameters and particular prognostic factors in prostate cancer treated with high–dose–rate brachytherapy (HDR–BT) as a boost
title_fullStr Correlation between treatment plan parameters and particular prognostic factors in prostate cancer treated with high–dose–rate brachytherapy (HDR–BT) as a boost
title_full_unstemmed Correlation between treatment plan parameters and particular prognostic factors in prostate cancer treated with high–dose–rate brachytherapy (HDR–BT) as a boost
title_short Correlation between treatment plan parameters and particular prognostic factors in prostate cancer treated with high–dose–rate brachytherapy (HDR–BT) as a boost
title_sort correlation between treatment plan parameters and particular prognostic factors in prostate cancer treated with high–dose–rate brachytherapy (hdr–bt) as a boost
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080389/
https://www.ncbi.nlm.nih.gov/pubmed/27799948
work_keys_str_mv AT chicheładam correlationbetweentreatmentplanparametersandparticularprognosticfactorsinprostatecancertreatedwithhighdoseratebrachytherapyhdrbtasaboost
AT kanikowskimarek correlationbetweentreatmentplanparametersandparticularprognosticfactorsinprostatecancertreatedwithhighdoseratebrachytherapyhdrbtasaboost
AT skowronekjanusz correlationbetweentreatmentplanparametersandparticularprognosticfactorsinprostatecancertreatedwithhighdoseratebrachytherapyhdrbtasaboost
AT dymnickamagdalena correlationbetweentreatmentplanparametersandparticularprognosticfactorsinprostatecancertreatedwithhighdoseratebrachytherapyhdrbtasaboost
AT piotrowskitomasz correlationbetweentreatmentplanparametersandparticularprognosticfactorsinprostatecancertreatedwithhighdoseratebrachytherapyhdrbtasaboost